Search

Current language : English

Building trust: ethics and responsibility are essential to health

Embody exemplary behaviour through responsible and transparent practices, placing ethics at the heart of our decisions and our impact.
Intégrité Header

Acting with integrity: responsible practices towards our stakeholders

Financial transparency, the absence of conflicts of interest and operational ethics are essential to the legitimacy and sustainability of pharmaceutical companies.
Ethics is a fundamental principle of the LFB, a duty that guides its actions and decisions, promoting responsibility, transparency and trust in all its activities.

Our evidence:

  • MAINTAINING AND ENSURING COMPLIANCE AND ETHICS IN THE CONDUCT OF GROUP BUSINESS: Train 100% of employees on the LFB Code of Conduct by 2028 ENSURING DIGITAL PRACTICES IN KEEPING WITH THE GROUP’S CSR COMMITMENTS: Raise awareness among 100% of affected employees about the LFB Responsible Digital Charter by 2027. SELECTING RELIABLE CSR SUPPLIERS AND SERVICE PROVIDERS: Promote suppliers and service providers that are aligned with our CSR commitments by 2030: - 70% of LFB’s purchases are made from suppliers assessed for their CSR compliance (via LFB’s CSR questionnaire or an EcoVadis rating). - Involve key suppliers in LFB’s CSR approach via an annual event starting in 2027. EVALUATING AND ENHANCING THE DONOR EXPERIENCE AND SOCIETAL IMPACT OF LFB’S PLASMA COLLECTION CENTRES: Ensure that, by 2030: - 90% of active donors have a good or excellent donation experience at our collection centres outside of France. - 80% of active donors recommend our collection centres to a friend or family member (Net Promoter Score). - Evaluate the societal impact of our collection centres and implement continuous improvement programmes. PROMOTING ANIMAL WELL-BEING: Carry out voluntary external audits to assess the living conditions of the animals used in the manufacture of our medicinal products, with a view to implementing continuous improvement programmes by 2030

Prevention of corruption at LFB

LFB has developed and implemented a corruption prevention program which it applies with “zero tolerance”. The anti-corruption code of conduct is one of the major tools of this programme.
This code applies to all LFB employees but also to external stakeholders (partners working for or with LFB) in France and abroad.
It describes the essential principles of a culture of integrity and the behaviours required in relations with all stakeholders.
It has been translated into 4 languages and is accompanied by a mandatory training programme for all LFB employees exposed to risks of corruption.

An alert line at alert-compliance@lfb.fr has been set up to bring to LFB’s attention, in a secure and confidential manner, any situation likely to be contrary to the principles described in this code.

LFB shows its commitment as part of its responsibilities towards blood donors, patients, healthcare professionals, its employees, partners, shareholder and society as a whole. LFB has implemented a corruption prevention programme based on zero tolerance towards any practice contrary to the fight against corruption and other integrity failures.

Download the PDF
Anticorruption code of conduct (cover of PDF document)

CONTEXT FOR UNDERSTANDING THE CHALLENGES

Integrity is key in the pharmaceutical sector: transparency, ethics and reliability are major expectations of patients, donors and all stakeholders. Maintaining their trust is essential. Beyond to good business practices, this requirement concerns particularly plasma donors.
Fully recognizing their contribution is key to maintaining their commitment and ensuring the legitimacy of the collection model.

Integrity is also expressed through responsible purchasing. Sector expectations include traceability and secure supply lines. Further social issues to be taken into consideration are those related to animal well-being, and responsible use of digital technologies, including cybersecurity, data protection and digital sobriety.
Integrity is a common thread that links respect for donors and sustainability of the value chain, and it is an essential lever for sustainable performance in the sector.

  • 71% of emissionsin the healthcare sector derive from the supply chain

  • Intégrité Image1

  • 7M animals used in 2022 in the EU and Norway for R&D*

  •

Find out more about the other pillars of our CSR Strategy:

Sources: